Stay updated on Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial page.

Latest updates to the Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial page
- Check5 days agoChange DetectedA new Revision label (v3.5.4) appears, replacing the previous v3.5.3. This reflects a minor product update to the page interface without altering study information.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedClinicalTrials.gov updated the page’s revision label from v3.5.2 to v3.5.3, indicating a site/version refresh rather than a change to the study record content.SummaryDifference0.1%

- Check34 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check63 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.1%

- Check77 days agoChange DetectedSite version updated from v3.4.2 to v3.4.3, with no visible changes to study details or page layout.SummaryDifference0.1%

- Check99 days agoChange DetectedRevision label updated from v3.4.1 to v3.4.2 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Poziotinib + T-DM1 in HER2+ Breast Cancer Clinical Trial page.